1. A design structure embodied in a machine readable storage medium for at least one of designing, manufacturing, and testing a design, the design structure comprising:
a memory module comprising:
a plurality of memories, each memory comprising a memory controller coupled to a memory array of memory pages, each of the memory pages comprising a corresponding locality tendency state;
a memory bank coupled to a sense amplifier and configured to latch selected ones of the memory pages responsive to the memory controller; and,
open page policy management logic coupled to the memory controller, the logic comprising program code enabled to granularly change open page policy management of the memory bank responsive to identifying a locality tendency state for a page loaded in the memory bank.
2. The design structure of claim 1, wherein the memories are dynamic random access memories (DRAMs).
3. The design structure of claim 1, wherein the tendency state is selected from a group of states comprising an open state, a weakly opened state, a strongly opened state and a closed state.
4. The design structure of claim 3, further comprising a locality tendency state machine managed by the open page policy management logic, wherein the locality tendency state for a memory page in the memory bank is determined by the state machine according to an occurrence of either a page hit or a page miss for the memory bank in satisfying a memory request in the memory controller.
5. The design structure of claim 1, further comprising a last page record for the memory bank indicating a last memory page closed from the memory bank.
6. The design structure of claim 1, wherein the design structure comprises a netlist, which describes the memory module.
7. The design structure of claim 1, wherein the design structure resides on the machine readable storage medium as a data format used for the exchange of layout data of integrated circuits.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of diagnosing cancer comprising:
obtaining an expression level of at least one Bcl-2 antagonist of cell death (BAD) pathway gene in a sample suspected of being cancerous or pre-cancerous;
using the expression level of the at least one Bcl-2 antagonist of cell death (BAD) pathway gene to obtain a BAD Pathway Gene Expression Signature (BPGES) score of the sample using Principal Component Analysis (PCA);
obtaining an expression level of a control;
using the expression level of the control to obtain a BAD Pathway Gene Expression Signature (BPGES) score of the control; and
comparing the BPGES score of the sample suspected of being cancerous or pre-cancerous to the BPGES score of the control sample;
wherein a lower BAD Pathway Gene Expression Signature (BPGES) score for the sample suspected of being cancerous or pre-cancerous as compared to the control sample is indicative of cancer;
wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, endometrial cancer, colon cancer, lung cancer, leukemia, brain cancer and melanoma.
2. The method of claim 1, wherein the at least one BAD pathway gene is selected from the group consisting of those genes listed in FIGS. 6 and 7.
3. The method of claim 1, wherein the cancer being diagnosed is pre-cancerous tissue, pre-invasive cancerous tissue, or invasive cancerous tissue.
4. A method of determining survival from cancer comprising:
identifying at least one BAD pathway gene differentially expressed in cells sensitive to at least one chemotherapeutic versus cells resistant to the at least one chemotherapeutic; and
comparing the least one BAD pathway gene in a sample suspected of being cancerous or pre-cancerous to a control sample;
wherein a lower differential expression of the at least one BAD pathway gene of the sample suspected of being cancerous or pre-cancerous as compared to the control sample is indicative of cancer non-survival;
wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, endometrial cancer, colon cancer, lung cancer, leukemia, brain cancer and melanoma.
5. The method of claim 4, wherein the chemotherapeutic is carboplatin, cyclophosphamide, topotecan, docetaxel, paclitaxel, or gemcitabine.
6. The method of claim 4, wherein the at least one BAD pathway gene is selected from the group consisting of genes listed in FIGS. 6 and 7.
7. A method of identifying cancer sensitivity to chemotherapeutics comprising:
obtaining a BAD Pathway Gene Expression Signature (BPGES) score of a sample suspected of being cancerous or pre-cancerous; and
comparing the BAD Pathway Gene Expression Signature (BPGES) score of the sample suspected of being cancerous or pre-cancerous to a control sample;
wherein the BAD Pathway Gene Expression Signature (BPGES) score identifies the chemosensitivity of cancerous or pre-cancerous cells to at least one chemotherapeutic;
wherein a low BAD Pathway Gene Expression Signature (BPGES) score is indicative of chemoresistant cancer.
8. The method of claim 7, wherein the chemotherapeutic is carboplatin, topotecan, docetaxel, gemcitabine and paclitaxel.
9. The method of claim 7, wherein the BAD Pathway Gene Expression Signature (BPGES) score is determined by obtaining an expression level of at least one BAD pathway gene selected from the group consisting of genes listed in FIGS. 6 and 7 and applying Principal Component Analysis (PCA).
10. A method of treating cancer comprising:
administering a therapeutically effective amount of an agent that targets the Bcl-2 antagonist of cell death (BAD) pathway;
wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, endometrial cancer, colon cancer, lung cancer, leukemia, brain cancer and melanoma.
11. The method of claim 10, wherein the agent modulates phosphorylation of BAD protein.
12. The method of claim 10, wherein the agent reduces level of active CDK1 or increases level of PP2C.
13. A method of monitoring neoplasia progression from one biological state to another in a tumor sample comprising:
obtaining a first BAD Pathway Gene Expression Signature (BPGES) score from a tumor sample at a first timepoint;
obtaining a second BPGES score from the tumor sample at a second timepoint wherein the second timepoint is at a given interval after the first timepoint; and
comparing the first and the second BPGES score to each other;
wherein a decrease in the second BPGES score as compared to the first BPGES score is indicative of neoplasia progression and an increase in the second BPGES score as compared to the first BPGES score is indicative of neoplasia regression;
wherein the neoplasia is selected from the group consisting of breast cancer, ovarian cancer, endometrial cancer, colon cancer, lung cancer, leukemia, brain cancer and melanoma.
14. The method of claim 13, wherein the BAD Pathway Gene Expression Signature (BPGES) score is determined by obtaining an expression level of at least one BAD pathway gene selected from the group consisting of genes listed in FIGS. 6 and 7 and applying Principal Component Analysis (PCA).
15. The method of claim 13, wherein the neoplasia progression being monitored is normal tissue to pre-cancerous tissue, normal to pre-invasive cancerous tissue, pre-cancerous tissue to pre-invasive cancerous tissue, or pre-invasive cancerous tissue to invasive cancerous tissue.